Zyn US shipment volume (pouches) in Q1 2027

Zyn's historical Q4 shipment strength is driven by commercial factors. Historically, fourth-quarter volumes for Zyn have demonstrated robust performance, with Q4 2024 shipments nearing 165 million cans and Q4 2025 reaching 196 million cans ^[1][2]. This seasonal pattern for Q4 is not consistently characterized as a sharp peak; instead, strong Q4 results have been attributed to factors such as inventory adjustments, promotional activities, and commercial initiatives rather than a recurring holiday effect ^[1][6][2]. For 2026, Philip Morris International's underlying quarterly shipment framework projected approximately 200 million cans in Q4, indicating a step-down from Q3 but remaining above Q2 ^[3][4][5]. The expansion of the portfolio in Q3 2026, which included ZYN ULTRA and new variants, was anticipated to bolster shipment growth and potentially increase the Q4 2026 run rate ^[3][4][5].

Q1 2027 volume estimates should reflect normalized 2026 quarterly ranges. The decline observed in Q1 2026, when shipments reached 155 million cans, was primarily due to distributor-inventory normalization, not a weakening of consumer demand ^[5][3][4]. Consequently, the Q1 2026 results should not be directly extrapolated to forecast Q1 2027 ^[5][3][4]. Instead, a reasonable directional benchmark for Q1 2027 is estimated to be around the normalized 2026 quarterly range, specifically 180–200 million cans, or 2.7–3.0 billion pouches ^[5][3][4].

FDA actions in early 2027 will primarily shape ZYN product dynamics. Q1 2027 ZYN shipment volumes are expected to be influenced by FDA regulatory actions, primarily affecting product mix, innovation timing, market share, and shipment timing, rather than causing an abrupt collapse in total volumes ^[1][2][4]. The existing authorized portfolio and demonstrated sequential recovery in shipment volumes support a quarterly run rate around the recent 2.9-billion-pouch level, with continued growth possible ^[1][2][4]. U.S. ZYN shipments initially declined to 2.3 billion pouches in Q1 2026, primarily due to distributor and trade inventory normalization ^[1][2]. However, Q2 2026 shipments rebounded to 2.9 billion pouches, a 25% sequential increase, with portfolio expansion highlighted as a contributing factor ^[2]

Read the full results here: 👉 https://lnkd.in/ehYvQPr6 | Philip Morris International U.S." aria-label="Source 3: Philip Morris International has announced its second quarter and first-half 2026 results.</p><p>Read the full results here: 👉 https://lnkd.in/ehYvQPr6 | Philip Morris International U.S." data-citation-label="Philip Morris International has announced its second quarter and first-half 2026 results.</p><p>Read the full results here: 👉 https://lnkd.in/ehYvQPr6 | Philip Morris International U.S.">[3].

Zyn maintained U.S. premium leadership despite early volume challenges. In 2026, Zyn held its position as the U.S. premium leader by retail value share, accounting for approximately 57% in Q2 ^[1]. However, its early-year volume growth significantly lagged Velo, and was only modestly ahead of on! by Q2/Q3 ^[2][5][4]. Zyn's shipment trajectory showed volatility, marked by a 23.5% year-over-year decrease in Q1 shipments, although shipments did recover in Q2 and Q3 ^[2][3][1].

Velo emerged as the fastest-growing competitor, aggressively gaining share. It reported a substantial 188% rise in U.S. modern-oral volume and a 209% increase in revenue during the first half of 2026 ^[4]. This growth led to a 10.4-percentage-point increase in Velo's U.S. modern-oral volume share, primarily driven by Velo Plus, indicating an aggressive gain in market share ^[2][5][4].

On! increased shipment volume but did not capture category growth as effectively. Altria’s on! experienced an increase in shipment volume, reaching 40.8 million cans in Q1 2026 and 47.2 million in Q2, with its first-half volume up 8.3% year over year ^[5]. While on! did grow in volume, it was less effective at capturing overall category growth compared to Velo ^[2][5][4]. Its oral-tobacco-category share was 8.6% in Q2 2026, an increase from 8.3% in Q2 2025 ^[5].

Third-party scanner data tracks Zyn's U.S. retail sales, not shipments. Zyn's U.S. sales trends are primarily monitored through third-party scanner data from sources such as Circana (formerly IRI) and NielsenIQ, which measure retail offtake rather than direct shipments ^[1][2][3]. The most actionable public source identified is the CDC Foundation's Monitoring Tobacco Product Use nicotine-pouch data brief, which utilizes Circana's weekly UPC-level sales covering convenience and multi-outlet retail channels, though it explicitly excludes online and tobacco-specialty stores ^[1][5]. However, the underlying Circana UPC data are restricted-use, and aggregate figures are constrained by vendor licensing, meaning direct, freely downloadable monthly Zyn sales tables are not available ^[1]. While purchasing access from Circana is an option, public secondary reporting can offer periodic directional insights from Circana and NielsenIQ, for example, Zyn's share of smokeless retail sales in past periods ^[8][9][10].

Scanner data for retail sales may differ from PMI's shipment volumes. A significant interpretation risk is that scanner data measures retail sell-through or offtake, which may not directly equate to Philip Morris International's (PMI) reported shipment volume due to inventory fluctuations ^[6][7]. Past instances have demonstrated divergence, where shipment volume decreased while consumer offtake increased after inventory normalization, or vice-versa ^[6][7]. Consequently, while scanner data can serve as an early signal for retail offtake for Q1 2027, it does not represent the direct settlement metric for prediction markets that resolve on PMI-reported Zyn U.S. pouch shipments ^[3].

UBS's early Zyn growth projections relied on specific market assumptions. UBS's earlier projections for Zyn's U.S. volume growth in 2027 targeted 13.8 billion pouches, representing approximately 21% annual growth ^[1]. This projection was predicated on assumptions including ZYN Ultra 9mg/11mg successfully capturing the higher-strength segment, which significantly contributes to category expansion, and ZYN's U.S. volume share stabilizing at around 42% from early 2027 ^[1]. It is important to note that this 21% figure constituted an earlier volume-led scenario, distinct from UBS's latest sales forecast, which was subsequently reduced to 3% following a roughly 25% reduction in pouch count for original dry cans ^[1][4]. Analysts are advised to differentiate between sell-in and consumer demand, as new variant distribution and pipelining have influenced shipments independently of scanner or offtake data ^[5]. Models that project this 21% annual volume growth imply Q1 2027 volumes of approximately 3.0–3.5 billion pouches, without factoring in launch pipelining or inventory shifts ^[1][2][3]. A direct seasonal allocation, assuming Q1 constitutes 25% of UBS's 13.8 billion-pouch annual case, suggests around 3.45 billion pouches for the quarter ^[1][2][3]. Conversely, applying Philip Morris International's historical quarterly pattern, Q1 would represent about 21.5% of annual volume, translating to roughly 3.0 billion pouches based on the 13.8 billion annual volume ^[1][2][3]. The shipment baseline can be noisy, with past Q1 outcomes often skewed by channel inventory ^[2][3]. While consumer demand may not be the primary downside risk for Q1, channel inventory movements pose a risk, whereas launch-related sell-in of new Ultra, flavors, and strengths could be an upside risk, potentially causing shipments to surpass scanner-based offtake during distribution expansion ^[3][2][5].

The Kalshi market offers insight into potential Q1 shipment volumes. The Kalshi market for Q1 2027 Zyn U.S. shipment volume (pouches), which resolves on April 21, 2027, presents thresholds including 3.5 billion, 3.7 billion, and 3.9 billion pouches ^[6]. This market should be interpreted as representing a distribution of potential outcomes rather than a single consensus point estimate ^[6].

The best base-case estimate for ZYN U.S. Q1 2027 shipments is approximately 3.3–3.6 billion pouches, with a central estimate near 3.45 billion ^[1]. This extrapolates from reported shipments of 2.3 billion in Q1 2026, 2.9 billion in Q2 2026, and 3.2 billion in Q3 2026 ^[1][2][3][4]. Management expected Q4 2026 to be broadly in line to modestly above Q3 ^[1][2][3]. Consumer offtake in Q1 2026 grew 10% while reported shipments fell 23.5% due to inventory normalization ^[2][3][4]. Q3 shipments increased 4.2% year over year, or 13% excluding prior-year promotional distortion ^[2][3][4]. Related prediction market data suggests confidence in full-year 2026 U.S. ZYN shipments above 10.6, 10.8, and 11.0 billion pouches, implying a strong Q4 2026 exit rate ^[5][6][7].

Bullish catalysts for Q1 2027 shipment volumes include an expanded ZYN portfolio, the introduction of new 1.5 mg and 8 mg variants, and ZYN Ultra ^[2][3]. Further support comes from improved category share, normalized inventories, and expanded Colorado manufacturing capacity ^[2][3]. The June 2026 FDA MRTP authorization for 20 ZYN SKUs also provides a positive tailwind ^[2][3].

Potential downside catalysts include intensified pouch competition and price sensitivity ^[2][3]. Execution risk during the transition from 15- to 20-pouch cans could weigh on performance, alongside lower revenue per pouch of approximately 25% on transitioned products ^[2][3]. Other headwinds are elevated U.S. commercial spending, manufacturing ramp costs, and regulatory uncertainty around products not covered by existing authorization ^[2][3]. Q4 2026 profitability was expected to be unusually low due to portfolio-transition support, higher marketing, and capacity investments; Q1 2027 margins could improve sequentially if the transition and investment peak pass, although revenue-per-pouch dilution may persist ^[2][6][7].